Risk of polymyxin B-induced acute kidney injury with a non adjusted dose versus adjusted dose based on renal function.

IF 1.7 4区医学 Q3 PHARMACOLOGY & PHARMACY

Personalized medicine Pub Date : 2022-07-01 Epub Date: 2022-06-28 DOI:10.2217/pme-2021-0003

Guanhao Zheng, Jiaqi Cai, Shenghui Zhou, Ning Du, Hao Bai, Juan He, Xiaolan Bian

引用次数: 0

Abstract

Aim: To observe the difference in the risk of polymyxin B (PMB)-induced acute kidney injury (AKI) with or without dose adjustment based on the patients renal function. Materials & methods: This retrospective cohort analysis was carried out in 115 patients treated with PMB from November 2018 to October 2019. Results: No significant difference in the incidence of AKI as well as secondary outcomes was observed between these two groups (47.5 vs 37.14%; p = 0.304). Conclusion: Dosing adjustment based on renal function does not significantly lower the risk of PMB-induced AKI. A non adjusted dosing strategy for PMB is recommended in patients exhibiting various levels of renal impairment.

查看原文本刊更多论文

多粘菌素b非调整剂量与基于肾功能调整剂量的急性肾损伤风险比较。

目的:观察多粘菌素B (PMB)引起的急性肾损伤(AKI)发生风险根据患者肾功能调整剂量与不调整剂量的差异。材料与方法:对2018年11月至2019年10月接受PMB治疗的115例患者进行回顾性队列分析。结果:两组AKI发生率及次要结局无显著差异(47.5% vs 37.14%;p = 0.304)。结论:基于肾功能的剂量调整并不能显著降低pmb诱发AKI的风险。对于表现出不同程度肾功能损害的患者，建议采用非调整的PMB给药策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Personalized medicine 医学-药学

CiteScore

3.30

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.